节点文献

白内障发病机制与防治策略的研究进展

Advances in pathogenesis and pharmacotherapy of cataract

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 徐靖杰张颖姚克陈祥军

【Author】 XU JingJie;ZHANG Ying;YAO Ke;CHEN XiangJun;Institute of Translational Medicine, Zhejiang University School of Medicine;Eye Center of the Second Affiliated Hospital, Medical College of Zhejiang University;

【通讯作者】 姚克;陈祥军;

【机构】 浙江大学医学院转化医学研究院浙江大学附属第二医院眼科中心

【摘要】 白内障是全球首位致盲性眼病.随着人口老龄化加剧,白内障将导致巨大的社会和经济负担.目前,手术治疗作为唯一的治愈手段,仍存在个体疗效差异、手术禁忌症、并发症及经济负担等诸多局限性,已不能满足当前社会需求.因此,研究白内障发病机制,找寻白内障潜在的治疗药物一直是研究的热点.本文基于团队目前的工作内容,从白内障发病机制、白内障模型进展及白内障防治药物的开发筛选等方面对白内障的发病机制及防治策略进行综述.

【Abstract】 Cataract is the leading cause of vision impairment worldwide. As the population ages, the prevalence of cataract will increase rapidly,which has caused a substantial social and economic burden. Although cataract surgery is effective, it still suffers from complications and high costs and could not meet the increasing surgery demand. Therefore, pharmacological treatment for cataracts is cheaper and more readily available for patients. Therefore, research on the pathogenesis of cataract and exploring potential therapeutic drugs for cataract have always been a research hotspot for years. Based on our team’s current work, this article summarizes the pathogenesis and pharmacotherapy strategies of cataract from the pathogenesis of cataract, the cataract disease models, and the development of anti-cataract drugs.

【关键词】 白内障发病机制药物防治
【Key words】 cataractpathogenesispharmacotherapy
【基金】 国家自然科学基金(批准号:31872724,81900837,82070939);浙江省科技厅基金(批准号:2019C03091)、浙江省科技厅重点研发计划(No.2019C03091)资助;浙江省自然科学基金(批准号:LR21H120001)
  • 【文献出处】 中国科学:生命科学 ,Scientia Sinica(Vitae) , 编辑部邮箱 ,2022年12期
  • 【分类号】R776.1
  • 【下载频次】194
节点文献中: 

本文链接的文献网络图示:

本文的引文网络